tirzepatide backorder FDA declares Mounjaro, Zepbound shortage over Compounders protest as FDA removes

Due to how common obesity is in the United States as well as the cost implications, if and when GLP-1 drugs are covered is a primary area of focus

This is the strongest and most legitimate evidence category for the molecule

While preliminary research suggests promising mechanisms of action, BPC-157 remains largely in the preclinical stage, with only a handful of small human trials published to date

The agreement calls for further price reductions over the next two years, and lower prices ($150) for oral GLP-1 medications when they are approved for obesity and become available

Examining the Evidence There is no established causal link between Wegovy and seizures based on current clinical evidence and regulatory data

It is also commonly prescribed off-label (for non-FDA-approved use) to help with weight loss and weight management in people with obesity or who are overweight with weight-related medical conditions